Isotretinoin and Hair Loss: A Clinical Perspective and Literature Review
Main Article Content
Keywords
Isotretinoin, Hair loss, Alopecia
Abstract
Isotretinoin, used for the treatment of moderate-to-severe acne, has many side effects due to its potent nature. While hair loss has been reported with isotretinoin use, there is limited data on the type and extent of hair loss. As hair loss poses a significant physical and psychological side effect to patients, it is important for dermatologists to consider and discuss this risk with their patients. According to a review of the literature, telogen effluvium is the most common type of hair loss reported, with some mention of androgenetic alopecia, lichen planopilaris, alopecia areata, and Darier disease.
We present the case of a 14-year-old male with moderate to severe acne, unresponsive to multiple topical and oral treatments, who was started on isotretinoin. After several months, he developed alopecia areata, which was initially treated with intralesional triamcinolone acetonide while continuing isotretinoin. Due to his worsening hair loss, isotretinoin was ultimately discontinued. Additional treatments, including topical steroids, oral dexamethasone, oral minoxidil, and an oral JAK inhibitor were introduced. While treatment remains ongoing, the patient has had near complete hair regrowth.
The onset of alopecia areata in our patient highlights the development of a unique form of alopecia that is not classically associated with isotretinoin use. While it is hypothesized that retinoids mediate hair loss via effects on the hair cycle and immune system, there is no direct explanation linking isotretinoin and alopecia areata.
References
2. Bhate K, Williams HC. Epidemiology of acne vulgaris. British Journal of Dermatology. 2013;168(3):474-485. doi:https://doi.org/10.1111/bjd.12149
3. Purdy S, DeBerker D. Acne vulgaris. BMJ Clinical Evidence. 2008;2008. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2907987/
4. Skroza N, Tolino E, Mambrin A, et al. Adult Acne Versus Adolescent Acne. The Journal of Clinical and Aesthetic Dermatology. 2018;11(1):21-25.
5. Barbieri JS. Isotretinoin for Treatment of Acne. JAMA Dermatology. 2023;159(12):1403. doi:https://doi.org/10.1001/jamadermatol.2023.2065
6. Isotretinoin - Drug Usage Statistics, ClinCalc DrugStats Database. clincalc.com. https://clincalc.com/DrugStats/Drugs/Isotretinoin
7. Lytvyn Y, McDonald K, Mufti A, Beecker J. Comparing the frequency of isotretinoin-induced hair loss at . JAAD International. 2022;6:125-142. doi:https://doi.org/10.1016/j.jdin.2022.01.002
8. Tran PT, Evron E, Goh C. Characteristics of Patients with Hair Loss after Isotretinoin Treatment: A Retrospective Review Study. International Journal of Trichology. 2022;14(4):125-127. doi:https://doi.org/10.4103/ijt.ijt_80_20
9. Vardhan A, Dinesh DC, Naidu M, Sharma S. ISOTRETINOIN INDUCED ALOPECIA -A CASE REPORT. ResearchGate. Published September 21, 2016. https://www.researchgate.net/publication/359369055_ISOTRETINOIN_INDUCED_ALOPECIA_-A_CASE_REPORT
10. Abdelmaksoud A, Temiz SA, Dursun R, et al. Isotretinoin‐induced hair disorders in the era of COVID‐19 and related vaccines: A case series. Journal of Cosmetic Dermatology. 2022;21(9):3651-3654. doi:https://doi.org/10.1111/jocd.15214
11. Kapała J, Lewandowska J, Placek W, Owczarczyk-Saczonek A. Adverse Events in Isotretinoin Therapy: A Single-Arm Meta-Analysis. International Journal of Environmental Research and Public Health. 2022;19(11):6463. doi:https://doi.org/10.3390/ijerph19116463
12. Aksac SE, Bilgili SG, Yavuz GO, Yavuz IH, Aksac M, Karadag AS. Evaluation of biophysical skin parameters and hair changes in patients with acne vulgaris treated with isotretinoin, and the effect of biotin use on these parameters. International Journal of Dermatology. 2021;60(8):980-985. doi:https://doi.org/10.1111/ijd.15485
13. Gupta M, Lotti T, Goldust M. Alopecia areata and isotretinoin; coincidence or causal relation. Dermatologic Therapy. 2020;33(3):e13280. doi:https://doi.org/10.1111/dth.13280
14. Tkachenko E, Singer SB, Sharma P, Barbieri J, Mostaghimi A. FDA Reports of Alopecia as an Adverse Event to Isotretinoin. Journal of Cutaneous Medicine and Surgery. 2019;23(4):451-452. doi:https://doi.org/10.1177/1203475419838553
15. İslamoğlu ZGK, Altınyazar HC. Effects of isotretinoin on the hair cycle. Journal of Cosmetic Dermatology. 2019;18(2):647-651. doi:https://doi.org/10.1111/jocd.12800
16. Faghihi G, Mokhtari F, Fard NM, Motamedi N, Hosseini SM. Comparing the Efficacy of Low Dose and Conventional Dose of Oral Isotretinoin in Treatment of Moderate and Severe Acne Vulgaris. Journal of Research in Pharmacy Practice. 2017;6(4):233-238. doi:https://doi.org/10.4103/jrpp.JRPP_17_30
17. Brzezinski P, Borowska K, Chiriac A, Smigielski J. Adverse effects of isotretinoin: A large, retrospective review. Dermatologic Therapy. 2017;30(4):e12483. doi:https://doi.org/10.1111/dth.12483
18. Demirseren DD, Kilinc F, Emre S, Akyol M, Metin A, Aktas A. The weeks and the cumulative doses of the first adverse events related to oral isotretinoin in acne patients: analysis of 300 patients. Journal of Dermatological Treatment. 2016;28(4):309-313. doi:https://doi.org/10.1080/09546634.2016.1230175
19. Kmieć ML, Pajor A, Broniarczyk-Dyła G. Evaluation of biophysical skin parameters and assessment of hair growth in patients with acne treated with isotretinoin. Advances in Dermatology and Allergology. 2013;6:343-349. doi:https://doi.org/10.5114/pdia.2013.39432
20. Gan EY, Koh WP, Jin A, Tan AWH, Tan HH, Tang MBY. Isotretinoin is safe and efficacious in Asians with acne vulgaris. Journal of Dermatological Treatment. 2013;24(5):387-391. doi:https://doi.org/10.3109/09546634.2012.672708
21. Duncan FJ, Silva KA, Johnson CJ, et al. Endogenous Retinoids in the Pathogenesis of Alopecia Areata. Journal of Investigative Dermatology. 2013;133(2):334-343. doi:https://doi.org/10.1038/jid.2012.344
22. Tosti A, Pazzaglia M. Drug Reactions Affecting Hair: Diagnosis. Dermatologic Clinics. 2007;25(2):223-231. doi:https://doi.org/10.1016/j.det.2007.01.005
23. Foitzik K, Spexard T, Nakamura M, Halsner U, Paus R. Towards Dissecting the Pathogenesis of Retinoid-Induced Hair Loss: All-Trans Retinoic Acid Induces Premature Hair Follicle Regression (Catagen) by Upregulation of Transforming Growth Factor-β2 in the Dermal Papilla. Journal of Investigative Dermatology. 2005;124(6):1119-1126. doi:https://doi.org/10.1111/j.0022-202x.2005.23686.x
24. Hull PR, Demkiw-Bartel C. Isotretinoin Use in Acne: Prospective Evaluation of Adverse Events. Journal of Cutaneous Medicine and Surgery. 2000;4(2):66-70. doi:https://doi.org/10.1177/120347540000400205
25. Berth-Jones J, Hutchinson PE. Novel cycle changes in scalp hair are caused by etretinate therapy. British Journal of Dermatology. 1995;132(3):367-375. doi:https://doi.org/10.1111/j.1365-2133.1995.tb08669.x
26. Hoover E, Alhajj M, Flores JL. Physiology, Hair. PubMed. Published July 30, 2023. https://www.ncbi.nlm.nih.gov/books/NBK499948/
27. Almohanna HM, Ahmed AA, Tsatalis JP, Tosti A. The Role of Vitamins and Minerals in Hair Loss: A Review. Dermatology and therapy. 2019;9(1):51-70. doi:https://doi.org/10.1007/s13555-018-0278-6
28. Gokce N, Basgoz N, Kenanoglu S, et al. An overview of the genetic aspects of hair loss and its connection with nutrition. Journal of preventive medicine and hygiene. 2022;63(2 Suppl 3):E228-E238. doi:https://doi.org/10.15167/2421-4248/jpmh2022.63.2S3.2765
29. Ahn D, Kim H, Lee B, Hahm DH. Psychological Stress-Induced Pathogenesis of Alopecia Areata: Autoimmune and Apoptotic Pathways. International Journal of Molecular Sciences. 2023;24(14):11711. doi:https://doi.org/10.3390/ijms241411711
30. Mubki T, Rudnicka L, Olszewska M, Shapiro J. Evaluation and diagnosis of the hair loss patient. Journal of the American Academy of Dermatology. 2014;71(3):415.e1-415.e15. doi:https://doi.org/10.1016/j.jaad.2014.04.070
31. Sellami R, Masmoudi J, Ouali U, et al. The relationship between alopecia areata and alexithymia, anxiety and depression: A case-control study. Indian Journal of Dermatology. 2014;59(4):421. doi:https://doi.org/10.4103/0019-5154.135525
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.